{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-094533","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2026-08-12T12:12:12+00:00","discovered_at":"2026-08-12T12:15:00.313858+00:00","generated_at":"2026-08-12T12:15:09.163075+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Century Therapeutics Q2 2026: Net loss $34.6M, cash $197.2M, CNTY-813 IND on track for 4Q26","bullets":["Q2 2026 net loss $34.6M vs $32.5M in Q2 2025; R&D $19.6M (down from $26.9M), G&A $5.8M (down from $7.8M).","Cash, equivalents and investments $197.2M at June 30, 2026, up from $117.1M at Dec 31, 2025; runway into 1Q 2029.","FDA pre-IND alignment for CNTY-813; IND submission on track for 4Q 2026, initial data expected 2H 2027.","CNTY-308, CD19-targeted CAR-iT therapy with Allo-Evasion 5.0, remains on track to enter clinic in 2026.","Preclinical data at ADA 2026 showed durable glucose control >8 months; oral presentations at EASD and CRC 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-094533","json":"https://secwatch.observer/filing/0001104659-26-094533.json","markdown":"https://secwatch.observer/filing/0001104659-26-094533.md","text":"https://secwatch.observer/filing/0001104659-26-094533.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926094533/0001104659-26-094533-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926094533/tm2622911d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T12:15:09.163075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}